Welcome to AiCuris: The Powerhouse for Anti-Infectives
AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
Pritelivir: Two Recent Publications
Publications Confirm the Potency of the Novel Anti-HSV Drug
Clinical data published in the peer-reviewed “Journal of Infectious Diseases”.... / Phase II data were used for the development of a mathematical model- published in "Science Translational Medicine”
Pritelivir topical development
Clinical development with topical Pritelivir started
An ongoing phase 1 trial in the U.S. has recruited 46 volunteers who are being treated with topical pritelivir against herpes simplex virus.
Join AiCuris and its quest for novel Anti-Infectives
We offer an exciting and challenging working enviroment in an innovative company with a world-class R&D Portfolio.